<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049293</url>
  </required_header>
  <id_info>
    <org_study_id>1610-ABU-074-HF</org_study_id>
    <nct_id>NCT03049293</nct_id>
  </id_info>
  <brief_title>Measurement of Midazolam Levels in Follicular Fluid</brief_title>
  <official_title>Measurement of Midazolam Levels in Follicular Fluid and Correlation of Midazolam Levels in Follicular Fluid and Oocyte Quality, Fertilization Rate, Embryo Development Pattern and Euploid Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Middle East Fertility Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Middle East Fertility Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the impact of Midazolam levels in follicular fluid on morpho-kinetics and
      morpho-genetics.

      The reason to measure Midazolam levels in larger size follicles in this study is to maximize
      the chances to get a mature oocyte and therefore develop into a potential embryo to be
      analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The correlation of Midazolam levels in follicular fluid and euploid status of the embryos is
      worth exploring as no data exists that suggests any influence on the quality of the embryos
      from using this substance for IVF since its earliest days. Measuring time lapsed from
      injection to first oocyte retrieval as well as time lapsed in between first and last oocyte
      retrieved will grand insight into the rise of levels of Midazolam inside the follicular
      fluid, correlated with the chromosomal status and the morphokinetic development of the
      euploid embryos.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Midazolam values measured by the time from the injection of Midazolam to the oocyte aspiration .</measure>
    <time_frame>6-12 months</time_frame>
    <description>To determine the impact of Midazolam levels in follicular fluid on morpho-kinetics and morpho-genetics.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Midazolam Overdose</condition>
  <arm_group>
    <arm_group_label>Control group using Propofol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group Midazolam group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>The impact of Midazolam levels in follicular fluid.</description>
    <arm_group_label>Study group Midazolam group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infertility (prim. / sec.)

          -  Age &gt;18 - ≤ 38 years.

          -  BMI 19-30

          -  Stimulation in GnRH-antagonist protocol, using rFSH

          -  Expected normal ovarian response (6)

          -  At least 4 follicles with the size ≥ than 17 mm on the day of OPU

          -  Patients undergoing PGS

          -  Able to understand the aim of the study and to provide consent

        Exclusion Criteria:

          -  History of endometriosis, classified according to the American Fertility Society (AFS)
             as stage 3 or more.

          -  Severe male factor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Human Mo Fatemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Middle East Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KAMPERI ELISSAVET, Study Nurse</last_name>
    <phone>+971 543205037</phone>
    <email>Elissavet.Kamperi@ivirma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IVI Middle East Fertilty Clinic</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVI Middle East Fertility clinic</last_name>
      <phone>+97126528000</phone>
      <email>info@ivirma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/7589618</url>
    <description>Follicular fluid levels of midazolam, fentanyl, and alfentanil during transvaginal oocyte retrieval.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/10402383</url>
    <description>Midazolam/ketamine sedative combination compared with fentanyl/propofol/isoflurane anaesthesia for oocyte retrieval.</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0952818001003312</url>
    <description>General anesthesia versus monitored anesthesia care with remifentanil for assisted reproductive technologies: effect on pregnancy rate</description>
  </link>
  <link>
    <url>http://humupd.oxfordjournals.org/content/20/1/124.long</url>
    <description>Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0015028210026877</url>
    <description>Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Middle East Fertility Clinic</investigator_affiliation>
    <investigator_full_name>Prof Dr. Human Fatemi</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>COPD,IVF</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

